Treating the Metabolic Syndrome With a Sodium-glucose Cotransporter-2 Inhibitor

PHASE3Enrolling by invitationINTERVENTIONAL

Enrollment

160

Participants

Timeline

Start Date

August 13, 2025

Primary Completion Date

August 31, 2026

Study Completion Date

December 31, 2026

Conditions

Metabolic Syndrome

Interventions

DRUG

Empagliflozin (oral)

Participants received Empagliflozin 10 mg orally once daily for six months.

OTHER

Matching placebo

Participants received matching placebo orally once daily for six months.

Trial Locations (1)

Queen Mary Hospital, Hong Kong

All Listed Sponsors

lead

The University of Hong Kong

OTHER